From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
Hazard Ratio
95% CI
P value
Age (< 60 vs > 60) **
1.85
1.24–2.77
0.003
Stage (II vs III and IV) **
1.90
1.28–2.83
0.001
T cells **
0.78
0.66–0.91
0.002
TMB **
0.94
0.91–0.97
< 0.001
Fibroblasts
1.18
0.98–1.42
0.076